A randomized, double-dummy, double-blind/open, parallel-group, phase-III, multicentre, 7-month study to assess the efficacy and safety of Symbicort Turbuhaler (budesonide/formoterol; 160/4.5 mcg delivered dose) given either as standard therapy (2 inhal. b.i.d.) or with an adjustable dosing regimen (1, 2 or 4 inhal. b.i.d.) versus Seretide Diskus (salmeterol/fluticasone; 50/250 mcg metered dose) given as standard therapy (1 inhal. b.i.d.) in adult and adolescent asthmatic patients.

Study identifier:SD-039-0686

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A randomized, double-dummy, double-blind/open, parallel-group, phase-III, multicentre, 7-month study to assess the efficacy and safety of Symbicort Turbuhaler (budesonide/formoterol; 160/4.5 mcg delivered dose) given either as standard therapy (2 inhal. b.i.d.) or with an adjustable dosing regimen (1, 2 or 4 inhal. b.i.d.) versus Seretide Diskus (salmeterol/fluticasone; 50/250 mcg metered dose) given as standard therapy (1 inhal. b.i.d.) in adult and adolescent asthmatic patients.

Medical condition

asthma

Phase

Phase 3

Healthy volunteers

-

Study drug

-

Sex

-

Actual Enrollment

-

Study type

Interventional

Age

-

Date

Study Start Date: 01 Oct 2001
Primary Completion Date: -
Study Completion Date: -

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Nov 2013 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria